中文         Site Map |
 
 
 
Fosun Pharma Announces Selection of Quintiles for First Global Post-Marketing Pharmacovigilance Outs
Date: Sep.2.2013
 
With its philosophy of continuous innovation in researching and manufacturing to international standards, Fosun Pharma, China’s leading healthcare company, is dedicated to providing safe and good quality products to improve healthcare.

Guilin Pharma, a subsidiary company of Fosun Pharma, recently signed an agreement with Quintiles, the world’s largest provider of biopharmaceutical development and commercial outsourcing services, to provide international post-marketing pharmacovigilance for Guilin Pharma’s antimalarial products.

Under the agreement, Quintiles began providing those post-marketing pharmacovigilance services for Guilin Pharma last month.

“We believe our Guilin Pharma subsidiary is the first Chinese domestic pharmaceutical company to start monitoring and management of a marketed drug internationally,” said Mr. Li Xianlin, Senior Vice President of Fosun Pharma and Chairman of the Fosun Pharmaceutical Industrial Management Committee.

Guilin Pharma is the only Chinese-local finished drug manufacturer approved by the World Health Organization (WHO) for its antimalarial products. Artesun, the original innovative brand product of Guilin Pharma, is recognized and recommended by WHO in over 20 malaria endemic countries as the gold standard for severe malaria treatment, and helps to save thousands of African children annually.

Guilin Pharma of Fosun Pharma acknowledges the importance of detection, assessment, understanding and prevention of adverse effects or any other drug-related problems in the product’s life-cycle, and always dedicates itself to improve the safety and efficacy of its products.

“We are pleased to have Quintiles, the world’s leading provider of biopharmaceutical services, to provide these post-marketing pharmacovigilance services,” Mr. Li Xianlin said. “We believe Quintiles’ network, its safety and pharmacovigilance professional team, as well as its advanced data management system, will help our Chinese local company go the extra mile and achieve full internationalism from development and manufacturing to commercialization.”
 

This site is published by Guilin Pharmaceutical (Shanghai) Corporation,        which is solely responsible for its content. All rights reserved.

© Guilin Pharmaceutical (Shanghai) Co., Ltd. 2017.

股市中有赚钱的散户吗6 吉林长春麻将吉祥棋牌 闲来陕西麻将苹果手机怎么下载 耳听八方四肖八码图片 大众麻将单机版 王者捕鱼游戏下载 正规的棋牌游戏? 北京赛车pk10投注平台 哪些股票值得投资 36选7复式票 四人打麻将免费版本